Second-line treatment for renal cell cancer.

The author discusses the significance of estabishing optimal sequence of administration for biological drugs for treatment of metastatic renal cell carcinoma (mRCC). The author cites that efficacy of data in patients treated with first-line pazopanib are lacking but mRCC sunitinib appears the best first-line choice. The author also notes that axitinib used as second-line of treatment for mRCC has proven to be valuable which yeilded meaningful progression-free survival (PFS) advantage.